Crossject Société Anonyme (EPA:ALCJ)

France flag France · Delayed Price · Currency is EUR
2.175
-0.010 (-0.46%)
Dec 5, 2025, 5:35 PM CET
10.41%
Market Cap 114.71M
Revenue (ttm) 4.07M
Net Income (ttm) -11.26M
Shares Out 52.74M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE 4.10
Dividend n/a
Ex-Dividend Date n/a
Volume 88,502
Average Volume 252,137
Open 2.190
Previous Close 2.185
Day's Range 2.165 - 2.240
52-Week Range 0.720 - 2.695
Beta 0.57
RSI 41.57
Earnings Date Dec 24, 2025

About Crossject Société Anonyme

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is dev... [Read more]

Sector Healthcare
Founded 2001
Employees 102
Stock Exchange Euronext Paris
Ticker Symbol ALCJ
Full Company Profile

Financial Performance

In 2024, Crossject Société Anonyme's revenue was 4.12 million, an increase of 6.28% compared to the previous year's 3.87 million. Losses were -12.80 million, 48.1% more than in 2023.

Financial Statements

News

There is no news available yet.